tiprankstipranks
Trending News
More News >
PILA PHARMA AB (SE:PILA)
:PILA

PILA PHARMA AB (PILA) AI Stock Analysis

Compare
1 Followers

Top Page

SE:PILA

PILA PHARMA AB

(PILA)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
kr1.00
▼(-54.55% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by weak financial performance (large ongoing losses and sustained cash burn) and bearish technicals (below all key moving averages with negative momentum). A clean, debt-free balance sheet and improved equity base provide some stability, while valuation remains hard to support due to negative earnings and no dividend data.
Positive Factors
Clean balance sheet / zero debt
Zero reported debt and a material equity increase improve solvency and reduce near-term default risk. This durable capital-structure strength gives management flexibility to fund clinical programs or raise capital from a stronger balance-sheet position, lowering financing risk.
Revenue rebound in 2025
A rebound in revenue demonstrates early commercial or milestone traction after declines, signaling that underlying operations can generate growing top-line receipts. Over 2-6 months, continued growth off this base would support scaling and validate aspects of the business model.
Focused therapeutic pipeline
A clear strategic focus on a single mechanism (TRPV1 antagonist XEN-D0501) concentrates R&D resources and clarifies milestone pathways. Focused pipelines can yield higher probability of meaningful progress per dollar invested and make partnership or licensing discussions more straightforward.
Negative Factors
Persistent negative free cash flow
Sustained negative operating and free cash flow indicates ongoing cash burn and dependence on external financing. Over months this constrains investment in trials, risks dilution on new raises, and forces management to prioritize programs, limiting long-term operational flexibility.
Widening net losses
Growing net losses erode equity and signal that operating costs outpace revenue growth. Persistently deep losses reduce runway, increase funding needs, and can delay commercialization or expansion plans, creating structural pressure on profitability and strategic options.
Small, volatile revenue and limited scale
A tiny, volatile revenue base and limited operating scale (1 employee reported) mean weak operating leverage and fragile commercial capability. The company remains highly dependent on R&D outcomes and external partners, increasing execution risk over the medium term.

PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)

PILA PHARMA AB Business Overview & Revenue Model

Company DescriptionPILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
How the Company Makes Moneynull

PILA PHARMA AB Financial Statement Overview

Summary
Overall financial profile is weak: small and volatile revenue, deeply negative profitability (net loss widened to -16.9m in 2025), and persistent negative operating/free cash flow (2025 FCF -9.2m). The main offset is a low-risk capital structure with zero debt and a stronger equity position in 2025, supporting near-term solvency despite ongoing losses.
Income Statement
18
Very Negative
Revenue is small and volatile, with a rebound in 2025 (1127k; +17.7% YoY) after declines in 2023–2024. Profitability is weak: 2025 shows deeply negative gross profit and very large operating losses, with net loss widening to -16.9m versus -11.2m in 2024. Margins are consistently negative across most years, indicating the business is still firmly in a cash-consuming, loss-making phase with limited operating leverage so far.
Balance Sheet
62
Positive
The balance sheet is relatively clean on leverage, with zero total debt in 2024–2025 and a 0.0 debt-to-equity ratio, reducing financial risk. Equity increased materially to 14.8m in 2025 from 5.3m in 2024, supporting solvency. The key weakness is persistent heavy losses (negative returns on equity in prior years), which can pressure the equity base over time if losses continue.
Cash Flow
24
Negative
Cash generation is weak, with operating cash flow and free cash flow negative every year shown (2025: -9.2m; 2024: -7.8m; 2023: -4.9m), indicating ongoing cash burn. While 2025 free cash flow improved versus 2024 (+11.7%), it remains deeply negative, and cash outflows have not stabilized at a sustainably lower level. The overall picture suggests continued reliance on external funding until losses narrow materially.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue957.89K1.13M775.00K1.46M1.88M719.23K
Gross Profit179.89K-6.82M-8.12M1.46M1.88M680.94K
EBITDA-7.04M-15.57M-10.11M-8.81M-26.76M-17.16M
Net Income-11.26M-16.86M-11.24M-9.93M-26.78M-17.21M
Balance Sheet
Total Assets3.48M16.22M6.22M8.46M10.89M31.81M
Cash, Cash Equivalents and Short-Term Investments1.08M15.90M4.89M5.95M7.24M28.21M
Total Debt0.000.000.00773.08K0.000.00
Total Liabilities2.32M1.43M963.00K1.79M1.36M1.51M
Stockholders Equity1.16M14.78M5.26M6.66M9.53M30.30M
Cash Flow
Free Cash Flow-8.22M-9.19M-7.82M-4.85M-9.09M-9.36M
Operating Cash Flow-8.22M-9.19M-7.82M-4.85M-9.09M-9.36M
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow6.76M20.19M6.76M3.56M-11.88M35.67M

PILA PHARMA AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.20
Price Trends
50DMA
1.51
Negative
100DMA
1.89
Negative
200DMA
2.28
Negative
Market Momentum
MACD
-0.08
Negative
RSI
42.15
Neutral
STOCH
21.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.51, and below the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 42.15 is Neutral, neither overbought nor oversold. The STOCH value of 21.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PILA.

PILA PHARMA AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
kr77.07M-1.64-106.95%-48.15%51.95%
44
Neutral
kr53.45M-601.02%
44
Neutral
kr142.58M-1.48-52.45%2.56%52.76%
43
Neutral
kr18.71M-1.19-88.65%8.46%11.73%
42
Neutral
kr90.17M-2.27-120.13%49.09%
41
Neutral
kr3.88M-3.06-213.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:PILA
PILA PHARMA AB
1.17
-1.88
-61.64%
SE:BIOSGN
Biosergen AB
38.40
-0.90
-2.29%
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.13
-91.91%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
5.30
-18.50
-77.73%
SE:NXTCL
NextCell Pharma AB
1.28
-2.06
-61.68%
SE:SPAGO
Spago Nanomedical AB
0.12
-0.02
-17.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026